Sanofi has signed an agreement with Evotec to integrate its infectious disease unit into the latter’s business.

Sanofi will pay €60m ($73.7m) in cash to Evotec along with funding for a five-year period, as part of the transaction.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The deal includes the transfer of ten R&D infectious disease assets of Sanofi to Evotec. Sanofi will retain certain option rights for development and commercialisation of the anti-infective products as part of the transaction.

Sanofi is a pharmaceutical company based in France, while Evotec is a German drug discovery and development company engaged in the manufacture of novel drugs.

The strategic collaboration will enable Evotec to expand its infectious disease research pipeline and accelerate the research and development of novel anti-infectives.

EBOS Group has secured a distribution deal to become the third-party distributor to more than 400 Chemist Warehouse and My Chemist stores across Australia.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The five-year supply agreement will be effective from July 2019.

EBOS Group anticipates the deal to generate an estimated revenue of $1bn within the first year.

Based in Australia, EBOS Group is a healthcare, medical and pharmaceutical products manufacturer and supplier, while Chemist Warehouse, also based in Australia, is an operator of retail pharmacies.

“EBOS Group has secured a distribution deal to become the third-party distributor to more than 400 Chemist Warehouse and My Chemist stores across Australia.”

Menarini Asia-Pacific Holdings has entered a licensing agreement with Orion to distribute and commercialise the latter’s Easyhaler® products in more than ten countries in the Asia-Pacific region.

Based in Singapore, Menarini Asia-Pacific Holdings is a biopharmaceutical company that markets and distributes pharmaceutical, biotechnology and consumer health products, while Orion is a Finland-based company involved in the development and marketing of pharmaceuticals.

The agreement enables the two companies to provide Easyhaler® products for the treatment of chronic obstructive pulmonary disease (COPD) and asthma.

Hemispherx Biopharma plans to raise $75m through a public offering of securities issued from time to time.

The company intends to issue the securities in any combination of common stock, preferred stock, debt securities, and warrants.

Silverman Shin & Byrne was appointed as the legal adviser to the company for the offering.

Based in the US, Hemispherx is a biopharmaceutical company focused on the development of new drugs.

MEDISCA has signed a three-year distribution agreement with FLAVORx to supply the full line of FLAVORx flavours in the Canadian market.

Based in Canada, MEDISCA is a provider of high-quality compounding solutions to the pharmaceutical compounding industry, while FLAVORx is a US-based supplier of inert medicine flavourings and flavouring systems to pharmacies.